SUM · NZX

Summerset Group Holdings (SUM)

Name: Summerset Group Holdings (SUM) financial result history
Creator: Annolyse

Healthcare / Retirement livingCovered: FY22 - HY268 published briefings

Summerset Group Holdings is an NZX-listed healthcare / retirement living company. Its latest covered result is HY26, with FY22 - HY26 of source-backed result history on Annolyse.

Sections

Latest metrics

HY26, released 27 August 2026

← Swipe to view more

SUM latest metrics
Metric	Value	Change
Revenue	$200.3m	↑ +15.7%
EBITDA	$140.5m	↑ +3.5%
NPAT	$171.4m	↑ +34.7%
Operating cash flow	$279.9m	↑ +22.4%
OCF / EBITDA %	199.2%	↑ +30.8pp
Net debt	$2.1b	↑ +11.3%
Net debt / EBITDA	14.65x	↑ +7.6%
ROE %	9.8%	↑ +5.8pp
DPS	3.8c	↓ -66.4%
Payout ratio vs NPAT %	5.4%Outside range low payout ratio versus npat. 5.4%; 3-period range 19.7% to 26%. Payout ratio versus NPAT: 5.4%, below normal range; 3-period mean 22.3%, range 19.7%-26.0%.	↓ -15.9pp

Source: latest published briefing (HY26, released 27 August 2026). Change compares against the prior equivalent period: HY25, released 28 August 2025.

Valuation

Trailing P/E, EV/EBITDA, price-to-book and price-to-free-cash-flow ratios combine the latest available close with filing data. They are comparative measures, not forecasts or recommendations.

Prices as at close, 18 September 2026

Price and market cap

The latest close and share count context for the market price.

Market cap

$1.9b

End-of-day close multiplied by current shares on issue.

Profitability multiples

How the market price compares with recent earnings and cash-flow inputs.

P/E

6.11x

Recent market cap compared with trailing earnings.

EPS

1.24

Recent filing-derived earnings per share.

PEG

0.18x

P/E compared with recent earnings growth.

EV/EBITDA

Not available

Not available for this company right now.

P/FCF

12.73x

Market cap compared with recent free cash flow.

P/B

0.53x

Market value compared with latest reported equity.

Income and investment-company measures

Yield and investment-company valuation where supported.

Dividend yield

2.2%

Trailing dividends compared with the latest close.

Total return

Not available

Available once dividend and adjustment data are verified.

Price history

Daily closes use the full available width, with hover and touch values for each observation. Expand the chart to see more detail.

Share price

Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.

Loading chart...

P/E over time

Filing-period markers only: EOD close on or before each release date divided by filing-derived trailing NPAT where both inputs verify.

Loading chart...

Chat

Ask about SUM

Ask follow-up questions about Summerset Group Holdings's latest result and company history.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about SUM

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Financial history

Performance over time

The latest period is shown first.

← Swipe to view more

SUM metric history
Metric	HY266 MONTHS27 August 2026	FY2512 MONTHS27 February 2026	HY256 MONTHS28 August 2025	FY2412 MONTHS28 February 2025	HY246 MONTHS26 August 2024	FY2312 MONTHS26 February 2024	HY236 MONTHS23 August 2023	FY2212 MONTHS24 February 2023	Trend
Revenue	$200.3m	$361.8m	$173m	$319.9m	$151.6m	$272.2m	$128.2m	$238.7m	Chart
Revenue growth %	15.7%	13.1%Outside range low revenue growth. 13.1%; 3-period range 14% to 17.5%. Revenue growth: 13.1%, below normal range; 3-period mean 15.9%, range 14.0%-17.5%.	14.1%	17.5%Outside range high revenue growth. 17.5%; 3-period range 13.1% to 16.2%. Revenue growth: 17.5%, above normal range; 3-period mean 14.4%, range 13.1%-16.2%.	18.2%Outside range high revenue growth. 18.2%; 3-period range 12.4% to 15.7%. Revenue growth: 18.2%, above normal range; 3-period mean 14.1%, range 12.4%-15.7%.	14.0%	12.4%Outside range low revenue growth. 12.4%; 3-period range 14.1% to 18.2%. Revenue growth: 12.4%, below normal range; 3-period mean 16.0%, range 14.1%-18.2%.	16.2%	Chart HY24 Revenue growth %: Outside range high revenue growth. 18.2%; 3-period range 12.4% to 15.7%. Revenue growth: 18.2%, above normal range; 3-period mean 14.1%, range 12.4%-15.7%. FY24 Revenue growth %: Outside range high revenue growth. 17.5%; 3-period range 13.1% to 16.2%. Revenue growth: 17.5%, above normal range; 3-period mean 14.4%, range 13.1%-16.2%. FY25 Revenue growth %: Outside range low revenue growth. 13.1%; 3-period range 14% to 17.5%. Revenue growth: 13.1%, below normal range; 3-period mean 15.9%, range 14.0%-17.5%.
EBITDA	$140.5m	—	$135.8m	$382.1m	$133.5m	$450m	$140.7m	$282.1m	Chart
EBITDA margin %	70.2%	—	78.5%	119.4%	88.0%	165.3%	109.7%	118.2%	Chart
PBT	$179.1m	$241.1m	$109.8m	$355.8m	$120.8m	$422.5m	$128.1m	$265.1m	Chart
PBT growth %	63.1%Outside range high pbt growth. 63.1%; 3-period range -9.1% to -5%. PBT growth: 63.1%, above normal range; 3-period mean -6.6%, range -9.1%--5.0%.	-32.2%	-9.1%Outside range low pbt growth. -9.1%; 3-period range -5.7% to 63.1%. PBT growth: -9.1%, below normal range; 3-period mean 17.5%, range -5.7%-63.1%.	-15.8%	-5.7%	59.4%Outside range high pbt growth. 59.4%; 3-period range -51.2% to -15.8%. PBT growth: 59.4%, above normal range; 3-period mean -33.1%, range -51.2%--15.8%.	-5.0%	-51.2%Outside range low pbt growth. -51.2%; 3-period range -32.2% to 59.4%. PBT growth: -51.2%, below normal range; 3-period mean 3.8%, range -32.2%-59.4%.	Chart HY25 PBT growth %: Outside range low pbt growth. -9.1%; 3-period range -5.7% to 63.1%. PBT growth: -9.1%, below normal range; 3-period mean 17.5%, range -5.7%-63.1%. HY26 PBT growth %: Outside range high pbt growth. 63.1%; 3-period range -9.1% to -5%. PBT growth: 63.1%, above normal range; 3-period mean -6.6%, range -9.1%--5.0%.
NPAT	$171.4m	$259.7m	$127.2m	$339.8m	$102.2m	$436.3m	$133.1m	$269.1m	Chart
NPAT growth %	34.7%Outside range high npat growth. 34.7%; 3-period range -23.2% to 24.5%. NPAT growth: 34.7%, above normal range; 3-period mean 0.1%, range -23.2%-24.5%.	-23.6%	24.5%	-22.1%	-23.2%Outside range low npat growth. -23.2%; 3-period range -1.1% to 34.7%. NPAT growth: -23.2%, below normal range; 3-period mean 19.4%, range -1.1%-34.7%.	62.1%Outside range high npat growth. 62.1%; 3-period range -50.5% to -22.1%. NPAT growth: 62.1%, above normal range; 3-period mean -32.1%, range -50.5%--22.1%.	-1.1%	-50.5%Outside range low npat growth. -50.5%; 3-period range -23.6% to 62.1%. NPAT growth: -50.5%, below normal range; 3-period mean 5.5%, range -23.6%-62.1%.	Chart HY24 NPAT growth %: Outside range low npat growth. -23.2%; 3-period range -1.1% to 34.7%. NPAT growth: -23.2%, below normal range; 3-period mean 19.4%, range -1.1%-34.7%. HY26 NPAT growth %: Outside range high npat growth. 34.7%; 3-period range -23.2% to 24.5%. NPAT growth: 34.7%, above normal range; 3-period mean 0.1%, range -23.2%-24.5%.
Operating cash flow	$279.9m	$548.2m	$228.7m	$443.2m	$191.6m	$398.2m	$146.7m	$369.2m	Chart
OCF / EBITDA %	199.2%	—	168.4%	116.0%	143.5%	88.5%	104.2%	130.9%	Chart
FCF pre-lease	$227.2m	-$98.9m	-$17.7m	-$168.2m	-$63.9m	$66.3m	$117.2m	-$264.7m	Chart
FCF post-lease	-$54.4m	—	-$17.7m	—	—	$66.3m	—	—	Chart
DPS	3.8c	13.2c	11.3c	13.2c	11.3c	13.2c	11.3c	11.6c	Chart
Payout ratio vs NPAT %	5.4%Outside range low payout ratio versus npat. 5.4%; 3-period range 19.7% to 26%. Payout ratio versus NPAT: 5.4%, below normal range; 3-period mean 22.3%, range 19.7%-26.0%.	22.7%	21.3%	16.9%	26.0%Outside range high payout ratio versus npat. 26%; 3-period range 5.4% to 21.3%. Payout ratio versus NPAT: 26.0%, above normal range; 3-period mean 15.5%, range 5.4%-21.3%.	13.1%	19.7%	19.1%	Chart HY24 Payout ratio vs NPAT %: Outside range high payout ratio versus npat. 26%; 3-period range 5.4% to 21.3%. Payout ratio versus NPAT: 26.0%, above normal range; 3-period mean 15.5%, range 5.4%-21.3%. HY26 Payout ratio vs NPAT %: Outside range low payout ratio versus npat. 5.4%; 3-period range 19.7% to 26%. Payout ratio versus NPAT: 5.4%, below normal range; 3-period mean 22.3%, range 19.7%-26.0%.
Annual payout ratio vs EPS %	—	22.7%	—	16.9%	—	13.1%	—	19.1%	Chart
ROE %	9.8%	7.8%Outside range low roe. 7.8%; 3-period range 11.5% to 16.8%. ROE: 7.8%, below normal range; 3-period mean 13.5%, range 11.5%-16.8%.	4.0%	11.4%	3.8%	16.8%Outside range high roe. 16.8%; 3-period range 7.8% to 12.3%. ROE: 16.8%, above normal range; 3-period mean 10.5%, range 7.8%-12.3%.	5.8%	12.3%	Chart FY25 ROE %: Outside range low roe. 7.8%; 3-period range 11.5% to 16.8%. ROE: 7.8%, below normal range; 3-period mean 13.5%, range 11.5%-16.8%.
Net debt	$2.1b	$2b	$1.8b	$1.7b	—	$1.4b	—	—	Chart
Net debt / EBITDA	14.65x	—	13.62x	4.46x	—	3.07x	—	—	Chart
Debtor days	106Outside range high debtor days. 106d; 3-period range 51d to 58d. Debtor days: 105.6 days, above normal range; 3-period mean 54.7 days, range 50.8 days-57.6 days.	9Outside range high debtor days. 9d; 3-period range 7d to 8d. Debtor days: 9.1 days, above normal range; 3-period mean 7.5 days, range 6.9 days-8.3 days.	51Outside range low debtor days. 51d; 3-period range 56d to 106d. Debtor days: 50.8 days, below normal range; 3-period mean 72.9 days, range 55.6 days-105.6 days.	8	56	7Outside range low debtor days. 7d; 3-period range 7d to 9d. Debtor days: 6.9 days, below normal range; 3-period mean 8.2 days, range 7.2 days-9.1 days.	58	7	Chart HY25 Debtor days: Outside range low debtor days. 51d; 3-period range 56d to 106d. Debtor days: 50.8 days, below normal range; 3-period mean 72.9 days, range 55.6 days-105.6 days. FY25 Debtor days: Outside range high debtor days. 9d; 3-period range 7d to 8d. Debtor days: 9.1 days, above normal range; 3-period mean 7.5 days, range 6.9 days-8.3 days. HY26 Debtor days: Outside range high debtor days. 106d; 3-period range 51d to 58d. Debtor days: 105.6 days, above normal range; 3-period mean 54.7 days, range 50.8 days-57.6 days.
Total assets	$9.8b	$9.2b	$8.7b	$8.1b	$7.4b	$6.9b	$6.3b	$5.8b	Chart

Reference: annolyse.ai/companies/sum

Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.

Filing-only history charts

These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.

Revenue

Reported revenue across covered periods.

Loading chart...

Revenue growth

Like-period revenue growth where comparable.

Loading chart...

EBITDA-equivalent

Company-specific earnings measure where disclosed.

Loading chart...

EBITDA margin

EBITDA-equivalent margin where revenue and earnings are source-backed.

Loading chart...

NPAT

Statutory profit after tax.

Loading chart...

Operating cash flow

Cash generated from operations.

Loading chart...

More financial metrics

Additional filing-backed metrics for this company. Each point links to the relevant published briefing.

OCF / EBITDA

Cash conversion against earnings.

Loading chart...

FCF pre-lease

Operating cash flow less capex before leases.

Loading chart...

FCF post-lease

Free cash flow after lease payments where available.

Loading chart...

ROE

Return on equity.

Loading chart...

Net debt

Borrowings less cash; negative values indicate net cash.

Loading chart...

Net debt / EBITDA

Leverage ratio, suppressed where earnings are not meaningful.

Loading chart...

DPS

Dividend per share declared for the period.

Loading chart...

Payout ratio

Dividend payout against statutory NPAT.

Loading chart...

Debtor days

Receivables days where the working-capital inputs are source-backed.

Loading chart...

Operating working-capital movement

Per-period working-capital absorption or release, from the same published history. Positive values are working-capital build; negative values are release.

Loading chart...

The setup & the reality

FY25 → HY26 Follow-through

The latest result is checked against what the prior briefing said to watch.

Historical setup

What FY25 said to watch

Previous analysisFY25Result released27 February 2026Annolyse analysis published21 April 2026

From PBT fell 32.2% on smaller revaluation gains; underlying profit up 13%

No formal FY26 financial targets are supplied in the release context, so this briefing assesses the result against the half-year trajectory rather than guidance. H1 FY25 contributed 47.8% of full-year revenue and 49% of NPAT, which is consistent with the company's slightly second-half-weighted shape and indicates that the H2 cadence broadly followed H1's improved sales momentum.

Management commentary in the half-year release flagged improving sales contract rates and growing stock under contract. The full-year volume outcome (1,560 ORA sales vs. 1,238) is consistent with that signal having carried through H2. What the release does not support is any read on the durability of revaluation gains, which drive a large share of reported IFRS profit and which compressed materially in FY25.

Open questions

Open questions from FY25

What was the FY25 investment property fair-value uplift, and how much of the PBT decline does it account for relative to other below-the-line items?
Why did the effective tax rate normalise from -4.5% to 7.7%, and is 7.7% representative going forward or itself unusually low?
How does management plan to evolve capex intensity, given $647.1m of capex against $361.8m of revenue and another $257.0m of borrowings drawn?
What is the trajectory of net debt and gearing as the land bank of around 5,500 units is built out, and at what point does development funding capacity constrain pipeline pace?
Is the 24.5 cents full-year dividend sustainable against ROE that has slipped from 11.4% to 7.8% while FCF before leases remains negative?

This briefing cannot assess the components of the investment property fair-value movement, the cost-to-build trajectory by village cohort, or forward unit pricing in either New Zealand or Australia from the disclosures supplied.

Latest result sources

Primary issuer documents used for the HY26 briefing. Document labels are preserved from the publication record; Annolyse does not relabel every financial report as an annual report.

Current period

Half Year Report

HY26 / financial report

Media Release

HY26 / media release

Results Announcement

HY26 / results announcement

Results Presentation

HY26 / results presentation

Prior comparable period

Half Year Report - 1H25

HY25 / financial report

Media Release - 1H25 Results

HY25 / media release

Results Announcement - 1H25

HY25 / results announcement

Results Presentation - 1H25

HY25 / results presentation

Full-year context

Annual Report FY25

FY25 / financial report

Media Release

FY25 / media release

Results Announcement

FY25 / results announcement

Results Presentation

FY25 / results presentation

Release context

Outcome of Summerset Annual Meeting

HY25 / commentary

NZX announcement - Summerset investor day presentation

HY26 / commentary

Outcome of Summerset Annual Meeting

HY26 / commentary

Peer context

Retirement living comparison set

These companies share the same curated sub-sector label. Their reporting definitions can still differ, so compare the underlying measures before ranking them.

OCA · HY26

Oceania Healthcare

7 published result briefings

RYM · FY26

Ryman Healthcare

7 published result briefings

Compare SUM, OCA, RYM →Healthcare result archive NZX healthcare comparison

Briefing archive

The full chronological archive contains every published result briefing.

HY26 · Released 27 August 2026

Underlying profit fell 3% while statutory PBT jumped 63.1%

Debtor days rose to 105.6 while underlying profit fell 3%, masking the drivers behind a 63.1% jump in statutory profit before tax.

Read briefing

FY25 · Released 27 February 2026

PBT fell 32.2% on smaller revaluation gains; underlying profit up 13%

IFRS earnings dropped on lower investment property fair-value uplifts, masking a 26% jump in unit settlements and 23.7% rise in operating cash flow.

Read briefing

HY25 · Released 28 August 2025

Underlying profit +19% on 692 sales, but NPAT flattered by tax swing

OCF rose 19.3% to $228.7m and gross borrowings grew 21.3% to $1.87b as $311.6m of development capex left free cash flow at -$17.7m.

Read briefing

FY24 · Released 28 February 2025

Underlying profit up 8% but development margin slipped and net debt grew NZ$322m

Statutory NPAT fell 22.1% on smaller fair-value gains while gross borrowings rose 23% to fund a NZ$611.4m build programme.

Read briefing

HY24 · Released 26 August 2024

Revenue up 18.2% but PBT fell 5.7% on 520bps development margin compression

A surge in development capex to $255.6m flipped free cash flow to -$63.9m and pushed net debt to $1,527.3m despite stronger occupation-rights cash

Read briefing

FY23 · Released 26 February 2024

NPAT up 62.1% but underlying profit grew just 11.0% on revaluation gains

Underlying profit of NZ$190.3m and 1,103 ORA sales describe a steadier operational result than the headline IFRS NPAT, while net debt rose NZ$332m.

Read briefing

Open all 8 result briefings

Get notified when SUM publishes

Get the next Summerset Group Holdings result briefing and five-year history updates by email.

Summerset Group Holdings (SUM)

Latest metrics

Valuation

Price and market cap

Profitability multiples

Income and investment-company measures

Price history

Share price

P/E over time

Ask about SUM

Ask about SUM

Sign in to chat

Performance over time

Filing-only history charts

Revenue

Revenue growth

EBITDA-equivalent

EBITDA margin

NPAT

Operating cash flow

More financial metrics

OCF / EBITDA

FCF pre-lease

FCF post-lease

ROE

Net debt

Net debt / EBITDA

DPS

Payout ratio

Debtor days

Operating working-capital movement

FY25 → HY26 Follow-through

What FY25 said to watch

Open questions from FY25

Latest result sources

Current period

Prior comparable period

Full-year context

Release context

Retirement living comparison set

Oceania Healthcare

Ryman Healthcare

Briefing archive

Underlying profit fell 3% while statutory PBT jumped 63.1%

PBT fell 32.2% on smaller revaluation gains; underlying profit up 13%

Underlying profit +19% on 692 sales, but NPAT flattered by tax swing

Underlying profit up 8% but development margin slipped and net debt grew NZ$322m

Revenue up 18.2% but PBT fell 5.7% on 520bps development margin compression

NPAT up 62.1% but underlying profit grew just 11.0% on revaluation gains

Compare this company

Get notified when SUM publishes